Viela Bio, Inc.

Viela Bio, Inc. (VIE) priced its initial public offering on Oct 4, 2019 at $19.00 per share, within its $19.00–$21.00 range, raising $150.1M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $943.7M. Goldman Sachs was lead-left underwriter, joined by Morgan Stanley, TD Cowen and Guggenheim. Mintz advised the company and Ropes & Gray advised the underwriters.

Viela Bio, Inc. is a clinical-stage biotechnology company developing treatments for autoimmune and severe inflammatory diseases by targeting biological pathways shared across indications. Its lead candidate, inebilizumab, is an anti-CD19 monoclonal antibody being developed first for neuromyelitis optica spectrum disorder.

Status

IPO

Ticker

VIE

Exchange

Nasdaq Global Select

Priced

Oct 4, 2019

IPO price

$19.00

Price range

$19.00–$21.00

Raised

$150.1M

Market cap at IPO price

$943.7M

First filed

Aug 29, 2019

Underwriters

Goldman Sachs, Morgan Stanley, TD Cowen and Guggenheim

Company counsel

Mintz

Underwriters' counsel

Ropes & Gray

Sector

Biotech & pharma

Country / state

MD

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.